



The 2022 Digital Learning Journey on Thyroid Disorders

OVERVIEW

Thyroid disorders is the umbrella term for several pathological conditions with high prevalence worldwide, such as hypothyroidism, hyperthyroidism, as well as both benign and malignant thyroid nodules. Overall, thyroid disorders are a major cause of global morbidity and decreased quality of life, and are of particular relevance for patients with critical comorbidities, such as patients with cardiac arrhythmias or hospital in-patients. For these patients, diagnosing or controlling the co-morbid thyroid disorder can have a major impact on the health and well-being of the patient. Critical to the issue of holistic patient care is awareness that several drugs used to treat common comorbidities, such as amiodarone, may increase the risk of thyroid dysfunction. This digital learning journey has been designed to provide participants with treatment strategies supported by evidence-based medicine to aid diagnosis and management of common thyroid disorders often presenting as clinical dilemmas.

LEARNING OBJECTIVES

Upon completion of the thyroid digital learning journey, participants will be able to:

- Recognize common thyroid disorders encountered in hospitals
- Formulate management plans to support patients from diagnosis through to treatment
- Define the metabolic consequences of thyroid dysfunction
- Apply international standards of care for managing different thyroid disorders, including drug-induced thyroid dysfunction and thyroid cancer

TARGET AUDIENCE

Endocrinologists, specialists in internal medicine, general practitioners

E-LEARNING ACTIVITIES

This learning journey is a structured e-learning educational program comprising:

1. Video Interview: Amiodarone and thyroid

LAUNCH: 30 April 2022

2. Online Course: Management of thyroid disorders in the hospital

LAUNCH: 30 September 2022

3. Video Lecture: Thyroid autoimmunity induced hypothyroidism

LAUNCH: 31 October 2022

4. Expert Perspective: The global rise of thyroid cancer: true emergency or false alarm

LAUNCH: 30 November 2022

LANGUAGE

All activities will be in English. The video interview will have subtitles and the video lecture will have a voiceover in both Spanish and Chinese (Mandarin).

This independent educational program is made possible thanks to an educational grant received from Merck Healthcare KGaA, Darmstadt, Germany.

